Posted by Michael Wonder on 14 Feb 2021
Biosimilars: is interchangeability the proof of the pudding?
15 February 2021 - While apparently non‐inferior to originator biologics, other factors need to be considered before switching
Biologic drugs are large monoclonal antibodies or genetically engineered proteins produced by live organisms. With highly specific targets, they have revolutionised the treatment of inflammatory, endocrine, and malignant conditions.
